Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;63(3):304-310.
doi: 10.1002/mus.27112. Epub 2020 Nov 13.

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Isabella Herman  1 , Michael A Lopez  2 , Dana Marafi  3 , Davut Pehlivan  1   3 , Daniel G Calame  1 , Farida Abid  1 , Timothy E Lotze  1
Affiliations

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Isabella Herman et al. Muscle Nerve. 2021 Mar.

Abstract

Background: The diagnosis of uncommon pediatric neuromuscular disease (NMD) is challenging due to genetic and phenotypic heterogeneity, yet is important to guide treatment, prognosis, and recurrence risk. Patients with diagnostically challenging presentations typically undergo extensive testing with variable molecular diagnostic yield. Given the advancement in next generation sequencing (NGS), we investigated the value of clinical whole exome sequencing (ES) in uncommon pediatric NMD.

Methods: A retrospective cohort study of 106 pediatric NMD patients with a combination of ES, chromosomal microarray (CMA), and candidate gene testing was completed at a large tertiary referral center.

Results: A molecular diagnosis was achieved in 37/79 (46%) patients with ES, 4/44 (9%) patients with CMA, and 15/74 (20%) patients with candidate gene testing. In 2/79 (3%) patients, a dual molecular diagnosis explaining the neuromuscular disease process was identified. A total of 42 patients (53%) who received ES remained without a molecular diagnosis at the conclusion of the study.

Conclusions: Due to NGS, molecular diagnostic yield of rare neurological diseases is at an all-time high. We show that ES has a higher diagnostic rate compared to other genetic tests in a complex pediatric neuromuscular disease cohort and should be considered early in the diagnostic journey for select NMD patients with challenging presentations in which a clinical diagnosis is not evident.

Keywords: diagnosis; exome; genetic; neuromuscular; pediatric; testing.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Fattahi Z, Kalhor Z, Fadaee M, et al. Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population. Clin Genet. 2017;91(3):386-402.
    1. Laing NG. Genetics of neuromuscular disorders. Crit Rev Clin Lab Sci. 2012;49(2):33-48.
    1. Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology. 2016;87(1):71-76.
    1. Dowling JJ, H DG, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A. 2018;176(4):804-841.
    1. Bhatt JM. The epidemiology of neuromuscular diseases. Neurol Clin. 2016;34(4):999-1021.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources